PMID- 26502836
OWN - NLM
STAT- MEDLINE
DCOM- 20160815
LR  - 20220321
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 12
IP  - 5
DP  - 2015 Nov
TI  - Ginsenoside Rh2 attenuates allergic airway inflammation by modulating nuclear 
      factor-kappaB activation in a murine model of asthma.
PG  - 6946-54
AB  - Allergic asthma is a chronic inflammatory disease that is regulated by 
      coordination of T-helper type 2 cell cytokines and inflammatory signaling 
      molecules. Ginsenoside Rh2 (G-Rh2) is an active component of ginseng with 
      anti-inflammatory and anti-tumor effects. The aim of the present study was to 
      determine the inhibitory effects of G-Rh2 on allergic airway inflammation in a 
      murine model of asthma, in which mice develop the following pathophysiological 
      features of asthma: Increased abundance of inflammatory cells; increased levels 
      of interleukin-4 (IL-4), IL-5 and IL-13; decreased abundance of interferon gamma 
      in the bronchoalveolar lavage fluid and lung tissue; increased total and 
      ovalbumin (OVA)-specific immunoglobulin E (IgE) levels in the serum; increased 
      airway hyperresponsiveness (AHR); and activation of nuclear factor kappa B 
      (NF-kappaB) in lung tissue. In the asthmatic mice, administration of G-Rh2 markedly 
      reduced peribronchiolar inflammation, recruitment of airway inflammatory cells, 
      cytokine production, total and OVA-specific IgE levels and AHR. G-Rh2 
      administration inhibited NF-kappaB activation and p38 mitogen-activated protein 
      kinase (MAPK) phosphorylation induced by OVA inhalation. These results suggested 
      that G-Rh2 attenuates allergic airway inflammation by regulating NF-kappaB activation 
      and p38 MAPK phosphorylation. The present study identified the molecular 
      mechanisms of action of G-Rh2, which supported the potential use of G-Rh2 to 
      prevent and/or treat asthma and other airway inflammatory disorders.
FAU - Li, Liang Chang
AU  - Li LC
FAU - Piao, Hong Mei
AU  - Piao HM
FAU - Zheng, Ming Yu
AU  - Zheng MY
FAU - Lin, Zhen Hua
AU  - Lin ZH
FAU - Choi, Yun Ho
AU  - Choi YH
FAU - Yan, Guang Hai
AU  - Yan GH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Ginsenosides)
RN  - 0 (Interleukin-13)
RN  - 0 (Interleukin-5)
RN  - 0 (NF-kappa B)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 78214-33-2 (ginsenoside Rh2)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Asthma/blood/*drug therapy/*immunology/pathology
MH  - Female
MH  - Ginsenosides/*therapeutic use
MH  - Immunoglobulin E/blood/immunology
MH  - Inflammation/blood/drug therapy/immunology/pathology
MH  - Interleukin-13/immunology
MH  - Interleukin-4/immunology
MH  - Interleukin-5/immunology
MH  - Lung/*drug effects/immunology/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - NF-kappa B/*immunology
MH  - Ovalbumin/blood/immunology
EDAT- 2015/10/28 06:00
MHDA- 2016/08/16 06:00
CRDT- 2015/10/28 06:00
PHST- 2014/10/22 00:00 [received]
PHST- 2015/07/21 00:00 [accepted]
PHST- 2015/10/28 06:00 [entrez]
PHST- 2015/10/28 06:00 [pubmed]
PHST- 2016/08/16 06:00 [medline]
AID - 10.3892/mmr.2015.4272 [doi]
PST - ppublish
SO  - Mol Med Rep. 2015 Nov;12(5):6946-54. doi: 10.3892/mmr.2015.4272.